GLX1546 / Galixir - LARVOL DELTA

Artificial intelligence (AI)-enabled discovery of GLX1546, a novel and potent inhibitor of ULK1/2 kinases and autophagy (AACR 2024) - "These results indicate that GLX1546 can inhibit ULK-mediated autophagy induced by trametinib. The combination of GLX1546 with RAS pathway inhibitors may offer a novel cancer therapy for RAS mutated cancers, highlighting AI as an effective tool for drug discovery."

Oncology • Solid Tumor • BRAF • KRAS